Antibody-drug conjugates in treatment-resistant hepatocellular carcinoma: mechanistic insights, translational barriers, and a blueprint for salvage-line precision oncology.
Several new antibody-drug combinations show early promise in advanced liver cancer patients who failed standard immunotherapy, offering meaningful rescue options.
This systematic review evaluates the emerging evidence for ADCs in treatment-resistant HCC following standard ICI-based therapy failure, identifying multiple candidates with promising early-phase activity. As HCC prognosis after ICI failure is dismal, ADCs represent a clinically urgent class of mechanistically distinct rescue therapies.
What the study was
- Study design
- Systematic review
- Population
- ICI-refractory hepatocellular carcinoma patients
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Biochimica et biophysica acta. Reviews on cancer
Why it surfaced
Systematic review of ADCs in ICI-refractory HCC—an unmet need with rapidly growing evidence base; contextualizes the evolving ADC therapeutic landscape for a high-mortality liver cancer.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.